Psychedelic Drug Therapy May Help Treat Alcohol Addiction
NEW YORK — Two doses of psilocybin, a compound found in psychedelic mushrooms, reduces heavy drinking by 83% on average among heavy drinkers when combined with psychotherapy, a new study shows.
Led by researchers at NYU Grossman School of Medicine, the investigation involved 93 men and women with alcohol dependence.
They were randomly assigned to receive either two doses of psilocybin or an antihistamine placebo. Neither the researchers nor the study participants knew which medication they received.
Within an eight-month period from the start of their treatment, those who were given psilocybin reduced heavy drinking by 83% relative to their drinking before the study began.
Meanwhile, those who had received antihistamine reduced their drinking by 51%.
Among the other key findings, the study showed that eight months after their first dose, almost half (48%) of those who received psilocybin stopped drinking altogether compared with 24% of the placebo group.
“Our findings strongly suggest that psilocybin therapy is a promising means of treating alcohol use disorder, a complex disease that has proven notoriously difficult to manage,” said Dr. Michael Bogenschutz, director of NYU Langone’s Center for Psychedelic Medicine and the study’s senior author.
The new study, published online in the journal JAMA Psychiatry, is the first placebo-controlled trial to explore psilocybin as a treatment for excessive alcohol consumption, according to the study authors.
The Centers for Disease Control and Prevention reports that excessive alcohol use kills roughly 95,000 Americans every year, often due to binge drinking or liver disease.
It is also linked to enormous economic and workplace losses, injury accidents, and impaired learning, memory, and mental health, said Bogenschutz, who is also a professor in the Department of Psychiatry at NYU Langone Health.
Current methods to prevent excessive alcohol use and dependency include psychological counseling, supervised detoxification programs, and certain drug regimens that dampen cravings.
For the investigation, the research team recruited men and women who were diagnosed with alcohol dependence based on standard definitions and consumed on average seven drinks on days when they drank.
Forty-eight patients received at least one dose and up to three doses of psilocybin, and 45 patients received the antihistamine placebo.
All received up to 12 psychotherapy sessions. These took place both before and after the drug treatments. Afterward, the participants were asked to report the percentage of heavy drinking days they experienced during weeks five to 36 of the study.
They also provided hair and fingernail samples to confirm that they had not been drinking. All participants were then offered a third session of psilocybin to ensure that those who previously received a placebo had the chance to be treated with the psychedelic drug.
“As research into psychedelic treatment grows, we find more possible applications for mental health conditions,” Bogenschutz said. “Beyond alcohol use disorder, this approach may prove useful in treating other addictions such as cigarette smoking and abuse of cocaine and opioids.”